AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 3.94 |
Market Cap | 6.34M |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -2.66 |
PE Ratio (ttm) | -1.55 |
Forward PE | n/a |
Analyst | Hold |
Ask | 4.28 |
Volume | 8,688 |
Avg. Volume (20D) | 22,277 |
Open | 4.32 |
Previous Close | 4.11 |
Day's Range | 3.93 - 4.32 |
52-Week Range | 2.78 - 5.20 |
Beta | undefined |
About XBIO
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor ...
Analyst Forecast
According to 1 analyst ratings, the average rating for XBIO stock is "Hold." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.
Next Earnings Release
Analysts project revenue of $230.00K, reflecting a -65.77% YoY shrinking and earnings per share of -0.2, making a -125.97% decrease YoY.